Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CTSL | P07711 | 7/20 | 0.50 |
| ▸ | CTSB | P07858 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10794620 | 1.00 | HTR2A (0.56) | HTR2AMEN1KMT2ACTSLCTSB | |
| SCHEMBL7333604 | 0.90 | HTR2A (0.53) | HTR2AMEN1KMT2ACTSLCTSB | |
| SCHEMBL7328473 | 0.90 | HTR2A (0.53) | HTR2AMEN1KMT2ACTSLCTSB | |
| SCHEMBL8433557 | 0.89 | CTSL (0.55) | MEN1KMT2ACTSLCTSBNPC1 | |
| SCHEMBL8433550 | 0.89 | CTSL (0.55) | MEN1KMT2ACTSLCTSBNPC1 | |
| SCHEMBL3881009 | 0.88 | CTSL (0.62) | CTSLCTSBCTSSCTSK | |
| SCHEMBL10366989 | 0.88 | CTSL (0.62) | CTSLCTSBCTSSCTSK | |
| SCHEMBL30404224 | 0.88 | CTSL (0.62) | CTSLCTSBCTSSCTSK | |
| SCHEMBL11415411 | 0.87 | CTSK (0.53) | HTR2ACTSLCTSBCTSK | |
| SCHEMBL1286216 | 0.87 | ELANE (0.59) | MEN1KMT2ACTSLCTSBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092088-A1 | PEPTIDE COMPOUND PRODUCTION METHOD | CHUBU UNIVERSITY EDUCATIONAL FOUNDATION (JP) | 2025-03-20 | — | — | US | disclosed |
| WO-2023136301-A1 | PEPTIDE COMPOUND PRODUCTION METHOD | 学校法人中部大学 | 2023-07-20 | — | — | WO | disclosed |
| US-20220289660-A1 | COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS | UNITED THERAPEUTICS CORPORATION (US) | 2022-09-15 | — | — | US | disclosed |
| US-11292758-B2 | Compounds and methods for delivery of prostacyclin analogs | UNITED THERAPEUTICS CORPORATION (US) | 2022-04-05 | — | — | US | disclosed |
| US-20220024845-A1 | COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS | UNITED THERAPEUTICS CORPORATION (US) | 2022-01-27 | — | — | US | disclosed |
| US-10947177-B2 | Compounds and methods for delivery of prostacyclin analogs | UNITED THERAPEUTICS CORPORATION (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200181057-A1 | COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS | UNITED THERAPEUTICS CORPORATION (US) | 2020-06-11 | — | — | US | disclosed |
| US-20190345091-A1 | COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS | UNITED THERAPEUTICS CORPORATION (US) | 2019-11-14 | — | — | US | disclosed |
| US-20180141891-A1 | COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS | UNITED THERAPEUTICS CORPORATION (US) | 2018-05-24 | — | — | US | disclosed |
| EP-2792353-B1 | Polymorph of Treprostinil diethanolamine salt | UNITED THERAPEUTICS CORP (US) | 2018-02-28 | — | — | EP | disclosed |
| US-4985361-A | GENETIC ENGINEERING | SANKYO COMPANY, LIMITED (JP) | 1991-01-15 | — | — | US | disclosed |
| EP-0198645-B1 | HUMAN PANCREATIC ELASTASE | SANKYO COMPANY LIMITED (JP) | 1990-11-22 | — | — | EP | disclosed |
| EP-0142231-B1 | PROCESS FOR PRODUCING SEQUENTIAL POLYAMINO ACID RESIN | NITTO BOSEKI CO., LTD. (JP) | 1987-11-11 | — | — | EP | disclosed |
| EP-0198645-A1 | Human pancreatic elastase | SANKYO COMPANY LIMITED (JP) | 1986-10-22 | — | — | EP | disclosed |
| US-4594409-A | Polycondensation of a peptide active ester salt | NITTO BOSEKI CO., LTD. (JP) | 1986-06-10 | — | — | US | disclosed |
| EP-0142231-A1 | Process for producing sequential polyamino acid resin | NITTO BOSEKI CO., LTD. (JP) | 1985-05-22 | — | — | EP | disclosed |
| US-4510241-A | BASED ON AXCTIVATING A PROCLOTTIN ENZYME FROM AN AMOEBA FROM HORSE | MALLINCKRODT, INC. (US) | 1985-04-09 | — | — | US | disclosed |
| EP-0094554-A1 | Test for esterase activity in a liquid sample | MILES LABORATORIES, INC. (US) | 1983-11-23 | — | — | EP | disclosed |
| US-4406832-A | Peptide-type substrates useful in the quantitative determination of endotoxin | MALLINCKRODT, INC. (US) | 1983-09-27 | — | — | US | disclosed |
| US-4237046-A | VASODILATION | BOARD OF REGENTS THE, THE UNIVERSITY OF TEXAS SYSTEM | 1980-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289660-A1 | COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS | PTGIR, PTGIS, PGF | HTR2A 940/4885MEN1 3275/4885KMT2A 4674/4885 |
| US-20220024845-A1 | COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS | PTGIR, PTGIS, PGF | HTR2A 940/4885MEN1 3275/4885KMT2A 4674/4885 |
| US-10947177-B2 | Compounds and methods for delivery of prostacyclin analogs | PTGIR, PTGIS, PGF | HTR2A 1063/4885MEN1 3087/4885KMT2A 4651/4885 |
| US-20250092088-A1 | PEPTIDE COMPOUND PRODUCTION METHOD | VIP, NPPA, HM13 | HTR2A 3844/4885MEN1 464/4885KMT2A 3104/4885 |
| US-11292758-B2 | Compounds and methods for delivery of prostacyclin analogs | PTGIR, PTGIS, PGF | HTR2A 1063/4885MEN1 3087/4885KMT2A 4651/4885 |
| US-20190345091-A1 | COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS | PTGIR, PTGIS, PGF | HTR2A 1063/4885MEN1 3087/4885KMT2A 4651/4885 |
| US-20180141891-A1 | COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS | PTGIR, PTGIS, PGF | HTR2A 1063/4885MEN1 3087/4885KMT2A 4651/4885 |
| US-20200181057-A1 | COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS | PTGIR, PTGIS, PGF | HTR2A 1063/4885MEN1 3087/4885KMT2A 4651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.